X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA AUROBINDO PHARMA ALEMBIC PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 16.6 13.8 120.8% View Chart
P/BV x 3.6 2.8 130.2% View Chart
Dividend Yield % 1.1 0.5 233.8%  

Financials

 ALEMBIC PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
AUROBINDO PHARMA
Mar-18
ALEMBIC PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs664809 82.1%   
Low Rs412504 81.8%   
Sales per share (Unadj.) Rs208.7281.1 74.3%  
Earnings per share (Unadj.) Rs31.041.4 75.0%  
Cash flow per share (Unadj.) Rs37.150.9 72.9%  
Dividends per share (Unadj.) Rs5.502.50 220.0%  
Dividend yield (eoy) %1.00.4 268.4%  
Book value per share (Unadj.) Rs144.2199.4 72.3%  
Shares outstanding (eoy) m188.52585.88 32.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.62.3 110.4%   
Avg P/E ratio x17.415.9 109.4%  
P/CF ratio (eoy) x14.512.9 112.4%  
Price / Book Value ratio x3.73.3 113.3%  
Dividend payout %17.76.0 293.5%   
Avg Mkt Cap Rs m101,461384,630 26.4%   
No. of employees `000NA17.3 0.0%   
Total wages/salary Rs m7,46721,308 35.0%   
Avg. sales/employee Rs ThNM9,500.7-  
Avg. wages/employee Rs ThNM1,229.4-  
Avg. net profit/employee Rs ThNM1,397.9-  
INCOME DATA
Net Sales Rs m39,347164,666 23.9%  
Other income Rs m941,020 9.2%   
Total revenues Rs m39,441165,686 23.8%   
Gross profit Rs m8,73637,718 23.2%  
Depreciation Rs m1,1525,580 20.7%   
Interest Rs m184777 23.7%   
Profit before tax Rs m7,49332,380 23.1%   
Minority Interest Rs m1131 34.4%   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5688,183 19.2%   
Profit after tax Rs m5,84424,229 24.1%  
Gross profit margin %22.222.9 96.9%  
Effective tax rate %20.925.3 82.8%   
Net profit margin %14.914.7 100.9%  
BALANCE SHEET DATA
Current assets Rs m19,577121,878 16.1%   
Current liabilities Rs m14,89686,806 17.2%   
Net working cap to sales %11.921.3 55.9%  
Current ratio x1.31.4 93.6%  
Inventory Days Days90130 69.1%  
Debtors Days Days4568 66.3%  
Net fixed assets Rs m27,09781,037 33.4%   
Share capital Rs m377586 64.3%   
"Free" reserves Rs m26,811116,218 23.1%   
Net worth Rs m27,188116,804 23.3%   
Long term debt Rs m4,9934,512 110.7%   
Total assets Rs m47,778211,052 22.6%  
Interest coverage x41.742.7 97.7%   
Debt to equity ratio x0.20 475.4%  
Sales to assets ratio x0.80.8 105.6%   
Return on assets %12.611.8 106.5%  
Return on equity %21.520.7 103.6%  
Return on capital %23.627.4 86.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45380,727 24.1%   
Fx outflow Rs m6,06534,700 17.5%   
Net fx Rs m13,38846,027 29.1%   
CASH FLOW
From Operations Rs m8,12019,548 41.5%  
From Investments Rs m-7,556-19,570 38.6%  
From Financial Activity Rs m5908,642 6.8%  
Net Cashflow Rs m1,1538,922 12.9%  

Share Holding

Indian Promoters % 74.1 54.1 137.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 8.0 36.5%  
FIIs % 9.1 27.7 32.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.2 136.3%  
Shareholders   49,328 69,601 70.9%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   JUBILANT LIFE SCIENCES  PLETHICO PHARMA  WOCKHARDT  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 250 Points; Metal & Realty Stocks Drag(12:30 pm)

Share markets in India are presently trading on a negative note. All sectoral indices are trading in red with stocks in the metal sector, realty sector and capital goods sector.

Related Views on News

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

More Views on News

Most Popular

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Driverless Cars are Here. And This Tiny Company is in the Lead...(The 5 Minute Wrapup)

Jul 17, 2019

This future-ready company thrives on the pace of technological change.

Here's Why This Smallcap Will Beat the Big Autos in the EV Race(Profit Hunter)

Jul 16, 2019

As the conventional auto sector faces existential crisis, my latest smallcap recommendation is all set to ride the electric vehicle disruption and rise in new age vehicles.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jul 24, 2019 02:31 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS